Clinical Trials Logo

Clinical Trial Summary

This study aims to assess efficacy and safety outcomes of a telehealth model of abortion care. The study will compare efficacy of this model to usual in-clinic care based on published rates. It will also investigate participant acceptability and feasibility of this model of care.


Clinical Trial Description

There are 2 components to the study: 1. A clinical records review on all patients 2. A survey study on a subset of patients who agree to participate. Clinical Records Review: We will examine medical chart data on all patients from partnered telehealth providers to analyze efficacy and safety outcomes for medication abortion. These medical chart data will include medical/pregnancy history and abortion outcome and de-identified apart from date of birth, zip code, and dates of service. Survey Study: Following completion of the telehealth provider's standard medical screening, all patients eligible to receive care through the telehealth provider will be directed to a page providing detailed information about the CHAT Evaluation Study and given the option to participate. Participation in the study involves completing our online questionnaires only. Being in the research study will not affect their care or treatment plan. Declining to participate in our research study will not affect their care. If interested, the patient will provide electronic consent and complete a baseline survey to report socio-demographic characteristics, pregnancy history, and reasons for interest in telehealth medication abortion services. An online follow-up survey will be administered 3-7 days after receiving mifepristone and then once again 4 weeks after taking mifepristone; assessments will include self-report of medication administration, adverse events, and satisfaction. Among those who complete the study surveys, we will investigate the feasibility, time to abortion, efficacy, safety, and acceptability of telehealth provision of mifepristone, measured using a 4-week follow-up though open-ended and closed-ended survey questions. Individuals who opted not to take the medications will be asked a separate set of follow-up questions to collect data related to diversion, to better understand potential risks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04432792
Study type Observational
Source University of California, San Francisco
Contact
Status Completed
Phase
Start date May 1, 2021
Completion date June 30, 2022

See also
  Status Clinical Trial Phase
Completed NCT03989869 - Very Early Medical Abortion N/A
Active, not recruiting NCT03736681 - Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage Phase 1
Completed NCT03636451 - Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage.o Phase 3
Recruiting NCT05182008 - A Patient Decision Aid for Method of Early Abortion: A Randomized Control Trial N/A
Completed NCT03417362 - Delivery of Audiovisual Information on Early Medical Abortion N/A
Completed NCT04824118 - Clotting Parameters After Medical Abortion
Recruiting NCT04458558 - Improving Access to Abortion in the Republic of Georgia Phase 4
Active, not recruiting NCT05278780 - Medication Abortion With Autonomous Self-Assessment Project N/A
Completed NCT03320057 - Medication Abortion Via Pharmacy Dispensing Phase 4
Not yet recruiting NCT05986357 - The Relation of High Sensitivity C Reactive Protein and Total Leucocytic Count Levels in Threatened Abortion
Completed NCT03047551 - Transabdominal and Transvaginal Sonography in Medical Abortion N/A
Completed NCT03913104 - Mail Order Mifepristone Study Phase 4
Terminated NCT04139382 - Using Telemedicine to Improve Early Medical Abortion at Home N/A
Recruiting NCT05147857 - Mid Trimester Abortion Effectiveness by Dilapan s N/A
Recruiting NCT05781061 - MA-ASAP at Independent Abortion Clinics: A Demonstration Project N/A
Completed NCT02522078 - Dry vs Wet Misoprostol for Cervical Dilation in First Trimester Abortion Phase 4
Completed NCT05635955 - Remimazolam Versus Propofol for Painless Abortion Phase 2
Active, not recruiting NCT05342974 - Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy Early Phase 1
Completed NCT03900728 - Auriculotherapy During Medication Abortion N/A